Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥6,174 JPY
Change Today -30.00 / -0.48%
Volume 1.3M
4502 On Other Exchanges
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - ¥6,657
52 Week Low
12/17/14 - ¥4,821
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, central nervous system, immunology and respiratory, general medicine, oncology, gastroenterology, and vaccines. The company has a partnership with Gencia LLC to develop a class of small molecule drugs as potential treatments for hematological and inflammatory diseases; and research collaboration with University College London to identify and validate novel target genes for the treatment of neurodegenerative disease. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Senior Vice Preside...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

U.S. FDA Approves Takeda’s NINLARO® (ixazomib), First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO® (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Takeda submitted a New Drug Application for NINLARO to the FDA in July 2015, and in September NINLARO was granted Priority Review status with a PDUFA date of March 10, 2016, reflecting the profound and continuing unmet need for new treatments for multiple myeloma, a devastating, relapsing and incurable rare cancer.

Takeda Pharmaceutical Company Limited Presents at Boston Biotech Conferences 2015, Nov-11-2015 01:00 PM

Takeda Pharmaceutical Company Limited Presents at Boston Biotech Conferences 2015, Nov-11-2015 01:00 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.

Takeda Pharmaceutical Company Limited to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting

Takeda Pharmaceutical Company Limited announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology annual meeting to be held in Orlando, Florida from December 5 to 8, 2015. It will be presenting pivotal data on the ixazomib program, as well as the five year overall survival data for ADCETRIS in relapsed/refractory Hodgkin lymphoma. The success of these two programs, in addition to data it will be presenting on VELCADE and its pipeline, is the realization of decades of commitment to patients with hematological malignancies. This is the first time Phase 3 data will be presented for ixazomib, an oral, once-weekly proteasome inhibitor which, if approved, would enable the first all-oral triplet regimen containing a proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma. Ixazomib is the first oral proteasome inhibitor in late stage clinical development. The TOURMALINE-MM1 study is an international, randomized, double-blind, placebo-controlled Phase 3 clinical trial which was designed to evaluate the superiority of once-a-week oral ixazomib plus lenalidomide and dexamethasone vs. placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Ixazomib has been granted Priority Review from the U.S. Food and Drug Administration and Accelerated Assessment by the Committee for Medicinal Products for Human Use of the European Medicines Agency, respectively, validating the profound and continuing unmet need for new multiple myeloma treatments. These submissions for the treatment of patients with relapsed and/or refractory multiple myeloma were based on the TOURMALINE-MM1 data.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,174.00 JPY -30.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.41 USD -0.04
Baxter International Inc $37.88 USD -0.16
Becton Dickinson and Co $150.12 USD -0.43
Biogen Inc $292.30 USD +3.15
Merck KGaA €96.59 EUR +0.341
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 203.6x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at